Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,336 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT07081555RecruitingPhase 1
Testing a new radioactive drug for HER2-positive advanced breast cancer
This trial tests a new radioactive drug, [177Lu]Lu-ABY-271, to see how safe it is and where it goes in the body. It is for people with HER2-positive breast cancer that has spread and cannot be removed by surgery.
GothenburgAges 18 years+ - NCT07078604RecruitingPhase 2
Vaccine with chemotherapy for advanced triple-negative breast cancer
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
Seattle, WashingtonAges 18 years+ - NCT06131775Recruiting
Study of immune cells in blood of people with solid tumors
This study is looking at a specific type of immune cell (called TLR4+ cells) in the blood of people with solid tumors. By studying these cells, researchers hope to learn more about how the immune system reacts to cancer and to treatments.
BronAges 18 years+ - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT07068542Recruiting
New drug combo for advanced thyroid cancer
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07069842Recruiting
Gastric cancer immunotherapy prediction model
This study looks at markers in your tumor to predict how well immunotherapy might work for you. It aims to create a model that helps doctors choose the best treatment for advanced gastric cancer.
Changzhi, ShanxiAges 18–75 - NCT07047365RecruitingPhase 3
New drug for HER2-positive advanced breast cancer
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Bengbu, AnhuiAges 18–75 - NCT07050394RecruitingEarly Phase 1
Experimental drug for advanced colorectal cancer
This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.
Shanghai, None SelectedAges 18 years+ - NCT07050186RecruitingPhase 2
Cemiplimab for advanced NUT carcinoma
This trial tests a drug called cemiplimab for people with NUT carcinoma that has spread or cannot be removed. The drug aims to shrink tumors or slow their growth.
Chicago, IllinoisAges 18 years+ - NCT07043400RecruitingPhase 3
Study comparing two ways to give tislelizumab plus chemo for stomach cancer
This trial compares a shot under the skin versus an IV infusion of tislelizumab, given along with chemotherapy, for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the shot works as well as the IV and may be more convenient.
Chandler, ArizonaAges 18 years+ - NCT06992648RecruitingPhase 3
Two drug combos for advanced colorectal cancer
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hangzhou, ZhejiangAges 18 years+ - NCT07037199RecruitingPhase 2
A new drug combo for HR+ advanced breast cancer
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07036380RecruitingPhase 2
Testing MP0317 with chemotherapy for advanced bile duct cancer
This trial tests if adding a new drug (MP0317) to standard chemoimmunotherapy helps people with advanced bile duct cancer. It's for patients who haven't had treatment yet, except for certain past adjuvant therapy.
BesançonAges 18 years+ - NCT07042919RecruitingPhase 1/Phase 2
Zanzalintinib for advanced liver cancer after prior treatment
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Chicago, IllinoisAges 18 years+ - NCT07039201Recruiting
A cell therapy for liver cancer that has progressed on other treatments
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
Hangzhou, ZhejiangAges 18–75 - NCT07032584Recruiting
Tele-rehab for rural men with metastatic prostate cancer
This trial tests a home-based exercise and support program delivered by phone or video for men with metastatic prostate cancer living in rural areas. The goal is to see if this approach improves quality of life and physical function compared to standard care.
Salt Lake City, UtahAges 21 years+ - NCT07020065RecruitingPhase 2
Reduced chemo plus immunotherapy vs immunotherapy alone for older lung cancer patients
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
Fribourg, Villars-sur-GlâneAges 70 years+ - NCT07011654RecruitingPhase 1/Phase 2
Study of two drugs for metastatic triple-negative breast cancer
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT06994377Recruiting
Emotional distress study for newly treated metastatic breast cancer
This trial studies emotional distress in people with metastatic breast cancer who have not yet received treatment for their advanced disease. It explores how different standard first-line therapies affect emotional well-being.
AnconaAges 18 years+ - NCT07001618RecruitingPhase 2
Fecal transplant with immunotherapy for advanced lung cancer
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
DijonAges 18 years+ - NCT06992739RecruitingPhase 2
Trilaciclib with chemotherapy for EGFR-mutant advanced lung cancer
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
Xiamen, FujianAges 18–75 - NCT06980272RecruitingPhase 3
A new drug for advanced lung cancer that hasn't been treated yet
This trial tests a new drug called SSGJ-707 for people with advanced non-small cell lung cancer who have not had prior treatment. It aims to see if the drug can help shrink tumors and improve outcomes.
ShanghaiAges 18 years+ - NCT06976190RecruitingPhase 3
MRG003 plus pucotenlimab vs chemo for advanced nasopharyngeal cancer
This trial tests whether combining an experimental antibody-drug conjugate (MRG003) with an immunotherapy (pucotenlimab) works better than standard chemotherapy for people with nasopharyngeal cancer that has come back or spread. If you have tried at least one prior treatment and are generally in good health, you may be able to join.
Guangzhou, GuangdongAges 18–75
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,336 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.